Workflow
Standard BioTools(LAB)
icon
搜索文档
Standard BioTools(LAB) - 2023 Q3 - Earnings Call Presentation
2023-11-08 08:49
业绩总结 - 公司在2023年第三季度实现了财务业绩[1] - 预计FY'23营收为1亿美元至1.05亿美元,非GAAP毛利率将提高约900个基点[19] - 预计Q1'24完成计划的合并,将建立多样化的技术领导地位和扩大市场[21] - 非GAAP毛利率从48.7%增至57.0%,YTD 2023从50.3%增至60.3%[26] 产品和技术 - 公司的营收主要来自仪器、耗材和服务等产品类别[9] - 公司的蛋白质组学业务推动增长,基因组学业务朝着实现正贡献率的目标前进[15] 财务数据 - 公司提供了非GAAP财务信息,包括非GAAP毛利率、非GAAP运营费用和调整后的EBITDA[3] - 在Q3 2023,研发支出、销售和管理支出、总非GAAP运营支出均有所降低[17] - 在YTD 2023,研发支出、销售和管理支出、总非GAAP运营支出均有所降低[17] - 在Q3 2023,现金运营支出从25百万美元降至11百万美元[18]
Standard BioTools(LAB) - 2023 Q3 - Earnings Call Transcript
2023-11-08 08:48
Standard BioTools Inc. (NASDAQ:LAB) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Peter DeNardo - IR Michael Egholm - CEO and President Jeff Black - CFO Conference Call Participants Operator Hello, and welcome to the Standard BioTools' Third Quarter 2023 Financial Results Conference Call. As a reminder this conference is being recorded. It is now my pleasure to introduce your host Peter DeNardo, Investor Relations. Thank you. Mr. DeNardo, you may begin. Peter DeNardo Than ...
Standard BioTools(LAB) - 2023 Q3 - Quarterly Report
2023-11-08 06:03
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to STANDARD BIOTOOLS INC. _____________________________________________ Commission file number: 001-34180 https://r ...
Standard BioTools(LAB) - 2023 Q2 - Earnings Call Transcript
2023-08-09 10:18
财务数据和关键指标变化 - 公司总收入在2023年上半年同比增长17%,其中第二季度收入同比增长47% [16][38] - 仪器收入在上半年同比增长超过70% [18][39] - 耗材和服务收入保持平稳或温和增长,占总收入约65% [41] - 毛利率在第二季度达到61%,同比提升2100个基点,上半年达到62%,同比提升1100个基点 [45][46] - 非GAAP经营费用在上半年同比下降26%,达到1800万美元 [49][50] 各条业务线数据和关键指标变化 - 蛋白质组学业务收入在第二季度同比增长74%,上半年增长38% [42] - 基因组学业务收入在第二季度同比增长15%,上半年下降8% [43] - 公司正在通过精简产品线、降低成本等措施来管理基因组学业务,将其维持在接近贡献利润平衡的水平 [44] 各个市场数据和关键指标变化 - 无具体披露 公司战略和发展方向及行业竞争 - 公司战略聚焦三大重点:稳定核心业务并实现增长、提升运营纪律以实现盈利和正现金流、利用并购推动规模、盈利和增长 [18] - 公司正在通过新产品推出、客户服务改善等措施来推动蛋白质组学业务的增长 [19][20][21][22] - 公司正在调整基因组学业务的策略,包括精简产品线、降低成本、拓展OEM合作等,以实现该业务的利润贡献 [23][24][25][26][27] - 公司正在积极寻求并购机会,利用自身的平台优势进行行业整合 [30][31][32] 管理层对经营环境和未来前景的评论 - 管理层表示对公司的进展感到鼓舞,但也保持谦逊态度,认识到仍有大量工作要做 [16][56][57][58] - 管理层提到当前宏观环境存在不确定性,因此暂不更新全年财务指引 [53][54] 其他重要信息 - 公司任命Jeff Black为新任首席财务官,接替离任的Vikram Jog [12][13][14] - 公司将参加即将到来的几个投资者会议,与投资者进一步交流 [59] 问答环节重要的提问和回答 无
Standard BioTools(LAB) - 2023 Q2 - Quarterly Report
2023-08-09 05:22
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to _____________________________________________ Commission file number: 001-34180 Delaware 77-0513190 State or other ju ...
Standard BioTools(LAB) - 2023 Q1 - Earnings Call Transcript
2023-05-10 08:32
Standard BioTools Inc. (NASDAQ:LAB) Q1 2023 Earnings Conference Call May 9, 2023 5:00 PM ET Company Participants Peter DeNardo - Investor Relations Michael Egholm - President and Chief Executive Officer Vikram Jog - Chief Financial Officer Operator Hello, and welcome to the Standard BioTools Incoporated First Quarter 2023 Financial Results Conference Call. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Peter DeNardo, Investor Relations. Thank you. Mr. DeNardo ...
Standard BioTools(LAB) - 2023 Q1 - Earnings Call Presentation
2023-05-10 07:44
BIOTOOLS Unleashing tools to accelerate breakthroughs in human health™ May 9, 2023 Legal Information This presentation and the accompanying oral presentation forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, guidance, including related to revenues, margin, and operating expenses, and statements regarding future financial performance and expectations, operational and strategic plans, deployment of capital, our cash runway and suffi ...
Standard BioTools(LAB) - 2023 Q1 - Quarterly Report
2023-05-10 05:13
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to _____________________________________________ Commission file number: 001-34180 STANDARD BIOTOOLS INC. (Exact name o ...
Standard BioTools (LAB) Investor Presentation - Slideshow
2023-03-25 00:59
Forward-Looking Statements operating results. Management uses non-GAAP measures to compare the company's performance relative to forecasts and strategic plans and to benchmark the company's performance externally against competitors. The time and amount of certain material items needed to estimate non-GAAP financial measures are inherently unpredictable or outside of our control. Material changes to any of these items could have a significant effect on guidance and future GAAP results. Non-GAAP information ...
Standard BioTools(LAB) - 2022 Q4 - Annual Report
2023-03-15 04:53
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 _____________________________________________ Commission file number: 001-34180 STANDARD BIOTOOLS INC. (Exact name of registrant as specified in its charte ...